tirzepatide deaths AHA 2024 - lowers the risk of worsening heart failure and CVD death for obese adults Tirzepatide for maintenance of bodyweight

For context, Eli Lillys existing weight loss drug Zepbound (Tirzepatide) generated $3.6 billion in a single quarter in Q3 2025 alone

doi: 10.1016/j.bcp.2020.114150 [DOI] [PubMed] [Google Scholar] 211.Ji L, Jiang H, Bi Y, et al

The pattern is clear: When people combine GLP-1 therapy with consistent digital engagement logging, reviewing feedback, staying connected to their data they lose more weight and maintain it better than those taking the same medications without that behavioral scaffolding

Adequate fiber helps stabilize blood sugar and promotes fullness

While these meds will likely make you feel full with less food, its what you eat that will determine how you feel and how nourished your body remains